C alcium ions play a fundamental physiologic role in signal transduction. An influx of Ca 2ϩ into cells is essential for skeletal muscle contraction, for myocardial contraction, for determining the tone of cardiac and vascular smooth muscle (and thus total peripheral resistance), for cardiac pacemaker activity, and for stimulating certain secretory cells. 1, 2 There is increasing evidence that Ca 2ϩ also has a role in cellular growth processes and tissue remodeling. The key sites and mechanisms regulating the passage of calcium across the plasma membrane and intracellular compartments are shown in Figure 1 . Of particular importance are voltage-gated Ca 2ϩ channels. 3 These channels are located in the plasma membrane, and are protein complexes that are voltage-gated to regulate Ca 2ϩ flow into the cell. 4 Calcium ions enter the cell once the channel is open due to the electrical and chemical gradients between the extracellular space and the intracellular compartment. Ca 2ϩ is actively transported out of the cell by an ATP-dependent calcium pump and the Na ϩ /Ca 2ϩ exchanger, located in the plasma membrane. The concentration of free Ca 2ϩ in the extracellular space is therefore many orders of magnitude higher than that inside the cell. The entry of Ca 2ϩ serves both as a depolarizing signal and as a cellular messenger to regulate cellular events, including muscle contraction.
All muscle cells interpret an increase in cytosolic calcium concentration as a signal to contract. Some muscles, for example, vascular smooth muscle, are stimulated directly by calcium that enters the cytosol from outside the cell. In others, such as skeletal and cardiac muscle, the calcium influx triggers a release of intracellular stores of Ca 2ϩ from the sarcoplasmic reticulum, which provides most of the activating Ca 2ϩ . 1 In the heart, the extracellular calcium accounts for only a small percentage of the activator calcium, but it does stimulate release of the intracellular calcium required for excitation-contraction. This has important clinical implications. Because calcium antagonists act at the cellular membrane, inhibiting the influx of extracellular calcium, they generally have a larger effect on cells that rely on extracellular calcium than on cells that recirculate intracellular calcium. Thus, calcium antagonists dilate coronary and peripheral arteries in doses that variably inhibit myocardial contractility and have little or no effect on skeletal muscle. 5 Their clinical usefulness in the treatment of hypertension and angina pectoris derives largely from these properties.
VOLTAGE-GATED CALCIUM CHANNELS
At least six classes of calcium channels have been identified (Tables 1 and 2). 1 N-, P-, Q-, and R-type channels are prominent in the central and peripheral nervous system. Only two types have been found in the cardiovascular system-the L-type and the T-type. L-Type calcium channels are present in cardiac and skeletal muscle, in vascular smooth muscle, and in certain secretory cells of the neuroendocrine system. They are involved in normal cardiac and vascular muscle electromechanical activity, admitting the substantial amounts of calcium needed to initiate muscular contraction. Calcium entry through L-type channels in the sinoatrial node contributes to pacemaker function, and in the atrioventricular node to the regulation of conduction. Traditional calcium antagonists-the dihydropyridines (eg, nifedipine), phenylalkylamines (eg, verapamil), and benzothiazepines (eg, diltiazem)-bind to and block calcium entry at L-type channels. They consequently have a significant effect on vascular smooth muscle, a lesser effect on other smooth muscle and the myocardium, and little effect on skeletal muscle. The L-type calcium channel is composed of several subunits, termed ␣ 1 , ␣ 2 , ␤, ␥, and ␦. The ␣ 1 -subunit is made up of four homologous domains and contains the transmembrane pore, through which calcium passes, as well as calcium antagonist binding sites, which are adjacent to the pore (Figure 2 ). The binding site of verapamil is located on the intracellular side of the plasma membrane. The nifedipine and diltiazem binding sites are on the extracellular surface, embedded in the membrane itself. These receptor sites are linked one to the other and with the calcium channel via allosteric linkages. 
THE T-TYPE CALCIUM CHANNEL
T-Type calcium channels were named as ''transient'' channels because of their apparently transient character relative to L-type channels; however, this inactivation rate depends greatly on experimental conditions and is not now considered a reliable indicator of channel type. 7 T-Type channels are activated and inactivated at more negative voltages than are L-type channels. 8, 9 The current-voltage relationship for a typical T-type channel is shown in Figure 3 . 10 They are activated at a more polarized membrane potential than the L-type channels, Ϫ60 mV compared to about Ϫ40 mV in the case shown. Furthermore, the T-type channel current reaches its peak at around Ϫ30 mV, whereas the L-type channel current has a peak at a potential of around ϩ10 to ϩ15 mV. T-Type channels can therefore be described as low-voltage-activated (LVA) channels. T-Type channel current is significantly less than L-type channel current ( Figure 3 ). T-Type calcium channels have several other distinctive characteristics ( Figure 3 ): they conduct Ca 2ϩ as much as Ba 2ϩ , whereas other calcium channels have a significantly greater conductance for barium than for calcium. 8, 11 Also, in contrast to other channel types, they inactivate faster at greater depolarizing voltages. 12 One of the most distinguishing characteristics is their slow rate of deactivation; that is, T-type channels return slowly from the open state to the resting (closed) state. They have deactivation rates typically in the range of 1 to 10 msec, while other calcium channels typically have deactivation rates of Ͻ 0.5 msec. This property has been found to be relatively independent of ionic conditions and has been measured using both the standard patch-clamp method and in single-channel measurements. The deactivation rate and the voltage-dependent rate of inactivation are possibly the most distinctive features of T-type channels. Calcium channels can also be distinguished by pharmacologic probes (Table 2) . T-Type channels are not very sensitive to dihydropyridine antagonists nor are they generally sensitive to the available toxins. 8, 13 Octanol and amiloride block T-type channels, but neither agent is selective nor effective across a variety of species and cell types.
The distribution of T-type channels differs substantially from that of L-type channels. Unlike L-type calcium channels, T-type channels are usually either not found, or are present at very low densities, in normal adult cardiac myocytes. 7, 14, 15 In the heart, the highest densities of T-type Ca 2ϩ currents are observed in pacemaker cells, such as those in the sinoatrial node and in Purkinje cells. 9, 16, 17 T-Type calcium currents are not thought to be essential to contractility, but they are probably crucial to impulse conduction and pacemaking, both of which rely on small currents at relatively negative potentials. The T-type channel current of atrial pacemaker and Purkinje cells begins at an activation potential of between Ϫ60 mV and Ϫ30 mV, at which activation and inactivation curves overlap. 16, 17 Vascular smooth muscle cells and smooth muscle cells from the stomach, intestine, and colon have also been found to contain T-type calcium channels. 18 -21 It is thought that they may help maintain muscle tone in such tissues. If this hypothesis is true, vascular tone would be increased by an increase in T-type channel currents and decreased by their pharmacologic blockage.
In secretory cells, calcium channels relay the signal that results in the release of hormones and transmitters. Because T-type channel activation and inactivation voltages overlap, substantial steady-state calcium current, and therefore secretion, can occur. T-Type channels have been identified in a variety of secretory cells, including pituitary cells, cortisol-secreting adrenal cells, calcitonin-secreting cells, and endocrine pancreatic cells. [21] [22] [23] [24] T-Type channels control the release of aldosterone in a variety of adrenal cells, 25 and may have a more general role in the control of the neuroendocrine axis. For example, the release of catecholamines from the adrenal medulla and from glomerulosa cells is controlled in part by LVA channels. T-Type channels likely regulate a larger number of processes than previously suspected.
In addition, T-type channels are believed to be involved in cell growth processes. A number of recent studies have linked T-type calcium channel activity to cell growth in physiologic, developmental, and pathologic conditions, eg, cardiac hypertrophy and injury repair. 26 -28 In a study of postnatal development of rat myocytes (Figure 4) , the L-type calcium channel density was independent of age, whereas T-type channel density increased up to about 4 to 5 weeks of age and declined rapidly thereafter. The pattern of cell growth 10 paralleled expression of T-type channels very closely, increasing up to about 5 to 6 weeks of age, then declining. 26 When T-type channel current is plotted against the rate of cell growth, there is a good linear correlation between the two processes ( Figure 4 , inset). In a study of cardiomyopathic Syrian hamsters, 28 both L-type and T-type calcium channels were found in normal and cardiomyopathic cells. However, while L-type channel current was the same in both types of cells, T-type channel current was more than twice as high in the cardiomyopathic cells than in the normal cells. Figure 5 shows the current-voltage relations of Land T-type channels in this study. These results strongly suggest a relationship between the overt expression of T-type channel activity and hypertrophic growth in this model of cardiac disease. Several other studies have reported that expression of T-type calcium channels increases when certain growth factors, such as growth hormone or endothelin-1, are present. 26, 29 Taken together, these findings certainly imply that T-type channels have a role in cell growth, although the mechanisms involved are still far from clear.
While T-type channels are not subject to ␤-adrenergic stimulation, T-type currents are increased by some neurohormones, including endothelin-1, angiotensin II, and ATP. 8, 30, 31 It is significant that both endothelin-1 and angiotensin II increase T-type currents and both are vasoconstrictors. 32, 33 Furthermore, endothelin-1 was found to increase T-type current in rat myocytes and simultaneously induce hypertrophy. 29, 34, 35 T-Type channels may also be involved in the proliferation of cardiac fibroblasts and the development of fibrosis. 36, 37 Table 3 summarizes the main differences between L-type channels and T-type channels.
PHARMACOLOGY OF T-TYPE CHANNELS
Mibefradil is a recently developed calcium channel blocker with a unique chemical structure, site of action, and set of pharmacologic and clinical effects. 38 Unlike other calcium antagonists, which block only L-type calcium channels, mibefradil acts on both Ltype and T-type calcium channels, but with a marked selectivity for T-type channels. Mibefradil differs 
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chemically from other calcium antagonists in that it is a nondihydropyridine with elements of phenylalkylamine and benzimidazolyl structures. 39 It also binds to the L-type calcium channel receptor in a unique manner (Figure 2 ). The compound interacts at both the verapamil binding site and the indolizine sulfone (SR 33557) site in a competitive manner, and at the diltiazem site in an undetermined manner. Unlike all other currently available calcium antagonists, mibefradil does not bind to the dihydropyridine receptor site. 39, 40 Mishra and Hermsmeyer 41 examined the effects of mibefradil on calcium channels using primary cultures of isolated rat vascular smooth muscle cells and the patch-clamp method. They used Ba 2ϩ as the extracellular divalent ion and reported that T-type channels were completely blocked by concentrations of mibefradil that only partially blocked L-type channel current. The effects of 10 mol/L mibefradil on the current-voltage relation and the maximum values of Tand L-type currents are shown in Figure 6 . Inhibition of T-type channel current resulted in a lower total current at lower voltages, at which the T-type channel part of the current is prominent, and little difference at higher voltages, at which the L-type channel current dominates. The T-type channel current in control (untreated) cells was reduced 85% by 1 mol/L mibefradil and to zero by 10 mol/L mibefradil. However, L-type channel current was only 25% lower in cells treated with 1 mol/L mibefradil and 66% lower with 10 mol/L mibefradil. Inhibition of calcium-channel current increased with increasing concentrations of mibefradil from 0.1 to 10 mol/L, with T-type channels always inhibited more than L-type channels. Fifty percent blockage of T-type channel current was observed at a concentration of about 0.1 mol/L. To rigorously test whether mibefradil would selectively block T-type channels after L-type channels were completely blocked, this study also examined the effects of mibefradil in combination with nisoldipine, a dihydropyridine selective for L-type calcium channels. Mibefradil blocked T-type channels after L-type current had already been completely blocked by nisoldipine. This finding is even more interesting because a 1 mol/L concentration of mibefradil correlates well with the plasma levels found to be therapeutically useful, eg, those having a significant antihypertensive effect. Mibefradil's selectivity for T-type over L-type channels (about 10-to 30-fold) has been confirmed in other types of cells. 42 The effects of T-type channel blockade on neointima formation after vascular injury have been studied using mibefradil as the blocker. 43 Mibefradil, amlodipine, verapamil, or saline were administered to rats starting 1 day before, and continuing for 14 days after balloon injury of the carotid artery. Mibefradil, amlodipine, and verapamil all lowered systolic blood pressure, but only mibefradil prevented the formation of neointima. At doses of 10 and 30 mg/kg body weight, the area of neointima was reduced by 31% and 48%, respectively. Neointima formation was decreased by 54% at the highest dose (P Ͻ .01 v control). In the same series of experiments, mibefradil, but not verapamil, 41 inhibited the in vitro growth of smooth muscle cells isolated from rat aortae. Because amlodipine and verapamil act only on the L-type calcium channel, whereas mibefradil acts primarily on the T-type channel, these results provide further evidence for the role of T-type channels in cell proliferation under pathologic conditions, and suggest that pharmacologic intervention of such growth may be possible.
A number of agents, including amiloride, flunarizine, and some insecticides, have shown activity at the T-type calcium channel, but they are all very nonselective in that they affect a variety of sites, the T-type channel often being the least significant. Mibefradil is unique in being selective for T-type channels. 4, 16, 44 
SUMMARY
Calcium channels and cellular Ca 2ϩ entry help regulate a number of crucial processes, among them cardiac, smooth, and skeletal muscle contraction, cardiac pacemaking and signal conduction, vascular tone, the neuroendocrine system, including the release of renin and aldosterone, and cellular growth and remodeling. There are significant differences between the two types of calcium channels in the cardiovascular system-the L-type and the T-type-both in distribution and function. Cardiac contractility is largely under the control of L-type channels. They are involved in normal cardiac and vascular muscle electromechanical activity, admitting the substantial amounts of calcium needed to initiate muscular contraction. Currently used calcium antagonists (the dihydropyridines, phenylalkylamines, and benzothiazepines) bind to and block calcium entry at L-type channels. T-Type calcium channels are activated and inactivated at much lower negative voltages than are L-type channels. Their current is significantly lower than L-type channel current and T-type channels return slowly from the open state to the resting state. In contrast to L-type channels, they are scarce in normal adult myocardium, but are prominent in conducting and pacemaker cells. Smooth muscle cells from the stomach, intestine, and colon, vascular smooth muscle cells, and certain secretory cells also contain T-type calcium channels. These channels are thought to help regulate pacemaking, signal conduction, vascular tone, and secretion of certain cellular transmitters. There is evidence that they have an important role in cell growth and tissue remodeling during normal development and in pathologic conditions such as cardiac hypertrophy. Mibefradil is a recently characterized calcium antagonist and the first that is selective for T-type calcium channels. It is thought that the ability of mibefradil to selectively block T-type channels will lead to major applications of this compound in cardiovascular medicine.
